valbenazine (ingrezza) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA

Active Ingredient History

  • Now
Valbenazine, sold under the trade name Ingrezza, is a medication used to treat tardive dyskinesia. It acts as a vesicular monoamine transporter 2 (VMAT2) inhibitor.   Wikipedia

  • SMILES: COc1cc2CCN3C[C@@H](CC(C)C)[C@@H](C[C@@H]3c2cc1OC)OC(=O)[C@@H](N)C(C)C.Cc4ccc(cc4)S(=O)(=O)O.Cc5ccc(cc5)S(=O)(=O)O
  • Mol. Mass: 762.99
  • ALogP: 3.56
  • ChEMBL Molecules:
More Chemistry
  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$145.1160 - $207.4890
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

ingrezza | mt-5199 | nbi-98854 | valbenazine | valbenazine tosylate | valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2h-benzo(a)quinolizin-2-yl ester


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue